Cerebrolysin
Neuropeptide Preparation | Neurological Recovery
Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement. Used clinically in 50+ countries.
Mechanism of Action
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors.
Key Benefits
- Direct brain delivery
- Standardized dosing
- Extensive clinical evidence
- Ready-to-use formulation
- Used clinically in 50+ countries
Bioactive peptide mixture Complex or non-standard sequence format
Cognitive
- Alzheimer's Disease
Meta-analyses show modest cognitive improvements, though clinical significance remains debated.
- Vascular Dementia
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.
- Post-Stroke Cognitive Recovery
Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit.
Neuroprotection
- Acute Stroke
Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement.
- Traumatic Brain Injury
Multiple trials including CAPTAIN series confirm GCS/GOS improvements.
- Subarachnoid Hemorrhage
Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies.
Recovery
- Motor Function Recovery
Some studies show enhanced recovery; results vary significantly between trials.
- Neurological Function
Early administration within 72 hours shows better outcomes than delayed treatment.
Primary administration route with well-established protocols for direct brain delivery via IV/IM.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Small Volume IV | Up to 10mL | Once daily | Undiluted IV slow push over 3 minutes |
| Intramuscular | Up to 5mL | Once daily | Undiluted IM injection over 3 minutes |
| Acute Stroke | 20-50mL | Once daily for 10-21 days | IV infusion (diluted to 100mL minimum) |
| Traumatic Brain Injury | 20-50mL | Once daily for 7-30 days | IV infusion (diluted to 100mL minimum) |
| Alzheimer's Disease | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
| Vascular Dementia | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
Reconstitution Instructions
- Cerebrolysin ampoules (5, 10, or 20 mL)
- Saline, Ringer solution, or 5% glucose (minimum 100 mL for infusion)
- Disposable one-way IV infusion sets and cannulas
- Sterile syringes and alcohol swabs
- 1 Break ampoule and extract Cerebrolysin immediately before use
- 2 For direct injection: Up to 10 mL IV undiluted (slow 3 minutes) or 5 mL IM
- 3 For infusion: Dilute 10-50 mL to minimum 100 mL with compatible solution
- 4 Start infusion immediately after dilution—infuse within 15 minutes
- 5 Flush IV catheter with sodium chloride before and after administration
- 6 Use disposable one-way infusion sets; discard after use
Safe combination with no significant interactions; both support cognitive function.
No interactions reported; may have synergistic cognitive effects in Alzheimer's treatment.
Potential additive neurotropic effects; monitor for enhanced antidepressant effects.
May have additive neurological effects; requires careful monitoring.
Contraindicated per prescribing information; do not mix in same infusion.
Should not be mixed in same IV infusion per official guidelines.
Compatibility issues; do not mix in same IV infusion.
Both enhance neurotrophic factors; potential additive effects—start with lower doses.
Initial neuroprotective effects; possible mild side effects (dizziness, agitation)
Neurological improvements become apparent; cognitive function may begin to improve
Continued recovery; motor function improvements in stroke/TBI patients
Sustained benefits; cognitive enhancement plateaus in chronic conditions
Common Side Effects
- Generally well tolerated
- Possible mild dizziness or agitation in early treatment
Stop Signs - Discontinue if:
- Severe allergic reactions (anaphylaxis, severe rash)
- New onset seizure activity
- Significant cardiovascular events during administration
- Severe renal dysfunction or worsening kidney function
Contraindications
- Epilepsy
- Severe renal insufficiency
- History of severe allergic reactions to porcine products
Good Signs
- Clear amber solution from reputable source
- Room temperature storage ≤25°C
- Protected from light in original carton
- Authorized EVER Pharma distributor
Warning Signs
- Some published studies have been retracted due to research misconduct; rely on independent meta-analyses
Bad Signs
- Frozen product or improper storage—never freeze
- Mixing with incompatible solutions (amino acids, vitamins, cardiovascular medications)
- CAPTAIN II Trial - Traumatic Brain Injury(2020)
Randomized controlled trial demonstrating efficacy and safety in moderate-severe TBI with improved GCS and GOS scores.
- Nine-Trial Stroke Meta-Analysis - Positive Results(2017)
Largest positive meta-analysis showing significant neurological improvements in 1,879 stroke patients with NNT=7.7.
- Conflicting Stroke Meta-Analysis - Neutral Results(2017)
Independent meta-analysis of 1,779 patients found no significant benefits in functional outcomes (mRS/BI).
- TBI Systematic Review - Positive Outcomes(2023)
Analysis of 8,749 TBI patients across 10 studies confirms statistically significant GCS/GOS improvements.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.